Head-to-head evidence
BBP-398 vs GH21
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline
BBP-398
Developed by Navire Pharma, a BridgeBio company
NCT05480865 · Phase 1 · terminated
This was an open-label, unblinded dose-escalation and expansion study without a comparator arm, in only 28 participants, so any tumor-response signal cannot be attributed to the drug combination with confidence. Results have not been posted yet.
GH21
Developed by Suzhou Genhouse Bio Co., Ltd.
NCT05183243 · Phase 1 · status unknown
This is an early-stage, single-group dose-finding study with no randomization, no blinding, and no comparison group, designed only to establish a safe dose. Studies of this type do not provide controlled evidence of benefit, and no results are available yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BBP-398's landscape · GH21's landscape